|Nombre||Título||Paga||Ejecutado||Año de nacimiento|
|Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc.||Executive Chairman of the Board, Global Chief Scientific & Medical Officer||629,19k||N/A||1953|
|Mr. Richard Gerald Adcock||President, CEO & Director||849,45k||N/A||1969|
|Mr. David C. Sachs||CFO, Principal Financial Officer & Principal Accounting Officer||533,33k||N/A||1978|
|Dr. Barry J. Simon M.D.||Chief Corporate Affairs Officer & Director||N/A||N/A||1965|
|Dr. Leonard S. Sender M.D.||Chief Operating Officer||N/A||N/A||N/A|
|Dr. Enrique Diloné Ph.D., RAC||Chief Technology Officer||N/A||N/A||1967|
|Mr. Jason R. Liljestrom||General Counsel & Corporate Secretary||N/A||N/A||1983|
|Ms. Sarah Singleton||Chief Communications Officer & Head of Patient Advocacy||N/A||N/A||N/A|
|Dr. Sandeep K. Reddy M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Dr. Hans Georg Klingemann M.D., Ph.D.||Chief Science Officer of Cellular||N/A||N/A||1950|
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.
El ISS Governance QualityScore de ImmunityBio, Inc., a día 1 de diciembre de 2023, es 8. Las puntuaciones base son Auditoría: 8; Tablero: 9; Derechos de los accionistas: 6; Compensación: 7.